Equities

Kilitch Drugs (India) Ltd

KILITCH:NSI

Kilitch Drugs (India) Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)367.45
  • Today's Change-2.55 / -0.69%
  • Shares traded25.65k
  • 1 Year change+62.59%
  • Beta0.9489
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments690591572
Total Receivables, Net658566430
Total Inventory109104137
Prepaid expenses0.861.580.50
Other current assets, total1.900.981.08
Total current assets1,4601,2641,141
Property, plant & equipment, net481474464
Goodwill, net194202211
Intangibles, net4.442.632.34
Long term investments228227261
Note receivable - long term7.156.214.63
Other long term assets------
Total assets2,4012,1952,098
LIABILITIES
Accounts payable256409429
Accrued expenses----0.04
Notes payable/short-term debt316222204
Current portion long-term debt/capital leases------
Other current liabilities, total705860
Total current liabilities642689693
Total long term debt000
Total debt316222204
Deferred income tax------
Minority interest(6.18)(10)12
Other liabilities, total1.720.682.75
Total liabilities638679708
SHAREHOLDERS EQUITY
Common stock161156156
Additional paid-in capital467383383
Retained earnings (accumulated deficit)1,007908782
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1246566
Total equity1,7631,5161,391
Total liabilities & shareholders' equity2,4012,1952,098
Total common shares outstanding161616
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.